Epigenetic profile in chronic lymphocytic leukemia using methylation-specific multiplex ligation-dependent probe amplification

Author:

Cosialls Ana M1,Santidrián Antonio F1,Coll-Mulet Llorenç12,Iglesias-Serret Daniel1,González-Gironès Diana M1,Pérez-Perarnau Alba1,Rubio-Patiño Camila1,González-Barca Eva3,Alonso Esther4,Pons Gabriel1,Gil Joan5

Affiliation:

1. Departament de Ciències Fisiològiques II, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)–Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain

2. Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Badalona, Barcelona, Spain

3. Departament d’Hematologia Clínica, IDIBELL–Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain

4. Servei d’Hematologia, IDIBELL–Hospital de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

5. Departament de Ciències Fisiològiques II, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)–Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.

Abstract

Aim: To analyze the methylation status of 35 tumor suppressor genes using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) in chronic lymphocytic leukemia (CLL). Materials & methods: The DNA of 37 samples from patients with CLL, six healthy donors, and Jurkat and Ramos cell lines was analyzed by MS-MLPA. Results: Our results confirm that hypermethylation is a common and not randomly distributed event in CLL, and some genes, such as WT1, CDH13, IGSF4/TSLC1, GATA5, DAPK1 and RARB, are hypermethylated in more than 25% of the analyzed samples. Importantly, MS-MLPA also detected hypermethylation of some genes not reported previously in CLL, and their methylation status was confirmed by bisulfite sequencing. Conclusion: These results indicate that MS-MLPA is a useful technique for the detection of methylation in CLL samples. Selecting CLL-specific methylation targets in order to generate a CLL-specific MS-MLPA probe set could enhance its usefulness as a tool in studies of risk stratification and guiding the best therapeutic decision.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Genetics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3